Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories

NEW YORK, March 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Biogen Idec Inc. Analyst Notes

On March 5, 2014, Biogen Idec Inc. (Biogen) announced that it has entered into collaboration with Eisai Co. Ltd (Eisai) to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401. Further, the agreement provides Eisai with an option to jointly develop and commercialize two of Biogen's candidates for AD, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.The Company informed that it will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments. Furthermore, the agreement also includes options for Eisai to receive an additional one-time payment from Biogen related to joint development and commercialization activities in Japan. "This collaboration is a natural fit with our mission to develop therapies for patients with severe neurodegenerative diseases. Eisai's candidates have demonstrated compelling early data and complement our AD research while extending our pipeline in this critical area," said George A. Scangos, Ph.D., CEO of Biogen. The full analyst notes on Biogen Idec Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/BIIB/report.pdf

Johnson & Johnson Analyst Notes

On March 6, 2014, Janssen-Cilag International NV (Janssen), a Johnson & Johnson company, announced that it has been granted conditional approval for SIRTURO (bedaquiline) by the European Commission (EC) in the European Union. The approval is for use of SIRTURO as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients, when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. "We are delighted that SIRTURO® has been approved for use in the European Union, as it represents a significant step forward in helping address a very serious global public health issue," said Wim Parys, Head R&D, Global Public Health at Janssen. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of bedaquiline on December 20, 2013. The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.AnalystsReview.com/03122014/JNJ/report.pdf

Express Scripts Inc. Analyst Notes

On February 27, 2014, Express Scripts Inc. (Express Scripts) announced the launch of a new Physician-Dispensed Medication Solution to provide workers' compensation payers visibility into their true total pharmacy costs and help reduce costs resulting from physician dispensing of medications. "When drugs are repackaged for physician-dispensing, the price is significantly inflated and those costs get passed on to the payers," said Jennifer Kaburick, Vice President, Workers' Compensation Product Management & Strategic Initiatives. "Processing bills for physician-dispensed medications through our enhanced adjudication system helps payers reduce costs, while staying compliant with state workers' compensation laws that address physician dispensing." The Company informed that the new solution is completely customizable based on the state jurisdiction. The full analyst notes on Express Scripts Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/ESRX/report.pdf

Merck & Co. Inc. Analyst Notes

On March 4, 2014, Merck & Co. Inc. (Merck) announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). Both doses of MK-8237 (at once-daily doses of 6 Development Units and 12 Development units) produced a significant dose- and time-dependent reduction in average TNSS over the last four hours of the chamber challenge at week 24 of treatment compared to placebo, the primary efficacy endpoint of the study. A Phase 3 study of MK-8237 in adolescents and adults with house dust mite-induced allergic rhinitis is currently screening patients. "We look forward to continuing with Phase 3 research, which will provide further insight into the safety and efficacy of MK-8237," said Dr. Sean Curtis, Vice President, Respiratory and Immunology, Merck Research Laboratories. The full analyst notes on Merck & Co. Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/MRK/report.pdf

Forest Laboratories Inc. Analyst Notes

On March 4, 2014, Forest Laboratories, Inc. (Forest) and Adamas Pharmaceuticals Inc., announced Forest's submission of a New Drug Application (NDA) to the Food and Drug Administration for a fixed-dose combination (FDC) of memantineHCl extended release (ER) and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer's type. "The concurrent use of memantine and donepezil is a well-established treatment option for patients with moderate to severe dementia related to Alzheimer's disease. Using the two drugs together appears to provide benefit over using acetylcholinesterase inhibitors alone. Reducing the number of pills by offering patients a fixed-dose combination helps lessen the daily medication burden and could improve patient adherence and compliance," said Pierre Tariot, MD, at the Banner Alzheimer's Institute. The full analyst notes on Forest Laboratories Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/FRX/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review